Biology Reference
In-Depth Information
[69] Depper JM, Leonard WJ, Drogula C, Kronke M, Waldmann TA, Greene WC. Interleukin
2 (IL-2) augments transcription of the IL-2 receptor gene. Proc Natl Acad Sci U S A
1985;82(12):4230-4.
[70] Siegel JP, Sharon M, Smith PL, Leonard WJ. The IL-2 receptor beta chain (p70): role in
mediating signals for LAK, NK, and proliferative activities. Science 1987;238(4823):75-8.
[71] Leonard WJ. Cytokines and immunodeficiency diseases. Nat Rev Immunol
2001;1(3):200-8.
[72] Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, et al. Interleu-
kin-2 receptor gamma chain mutation results in X-linked severe combined immunode-
ficiency in humans. Cell 1993;73(1):147-57.
[73] Friedmann MC, Migone TS, Russell SM, Leonard WJ. Different interleukin 2 receptor
beta-chain tyrosines couple to at least two signaling pathways and synergistically me-
diate interleukin 2-induced proliferation. Proc Natl Acad Sci U S A 1996;93(5):2077-82.
[74] Lin JX, Migone TS, Tsang M, Friedmann M, Weatherbee JA, Zhou L, et al. The role of
shared receptor motifs and common Stat proteins in the generation of cytokine pleiot-
ropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 1995;2(4):331-9.
[75] Sykes M, Romick ML, Hoyles KA, Sachs DH. In vivo administration of interleukin 2 plus
T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and
permits alloengraftment. J Exp Med 1990;171(3):645-58.
[76] Sykes M, Romick ML, Sachs DH. Interleukin 2 prevents graft-versus-host disease while
preserving the graft-versus-leukemia effect of allogeneic T cells. Proc Natl Acad Sci
U S A 1990;87(15):5633-7.
[77] Sykes M, Harty MW, Szot GL, Pearson DA. Interleukin-2 inhibits graft-versus-host
disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated
graft-versus-leukemia effects. Blood 1994;83(9):2560-9.
[78] Wang MG, Szebeni J, Pearson DA, Szot GL, Sykes M. Inhibition of graft-versus-host
disease by interleukin-2 treatment is associated with altered cytokine produc-
tion by expanded graft-versus-host-reactive CD4+ helper cells. Transplantation
1995;60(5):481-90.
[79] Shin H-J, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS. Rapamycin and
IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion
of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 2011;118(8):2342-50.
[80] Robb RJ, Lineburg KE, Kuns RD, Wilson YA, Raffelt NC, Olver SD, et al. Identification
and expansion of highly suppressive CD8+FoxP3+ regulatory T cells after experimental
allogeneic bone marrow transplantation. Blood 2012;119:5898-908.
[81] Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular
and cellular mechanisms. Ther Drug Monit 1995;17(6):584-91.
[82] Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse
after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994;84(3):964-71.
[83] Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al. IL-2 regulates FOXP3
expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mecha-
nism and induces the expansion of these cells in vivo. Blood 2006;108(5):1571-9.
[84] Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea 3rd EP, et al.
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med
2011;365(22):2055-66.
[85] Abhyankar S, Gilliland DG, Ferrara JL. Interleukin-1 is a critical effector molecule
during cytokine dysregulation in graft versus host disease to minor histocompatibility
antigens. Transplantation 1993;56(6):1518-23.
[86] Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory dis-
eases. Blood 2011;117(14):3720-32.
[87] Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately
regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998;28(8):2598-602.
[88] Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signaling 2010;3(105);
cm1.
[89] Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87(6):2095-147.
[90] Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, et al. Interleukin-1 type II
receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993;261(5120):472-5.
[91] McCarthy Jr PL, Abhyankar S, Neben S, Newman G, Sieff C, Thompson RC, et al. Inhibi-
tion of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host
disease. Blood 1991;78(8):1915-8.
[92] Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, et al. Interleukin-1
blockade does not prevent acute graft-versus-host disease: results of a randomized,
double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in alloge-
neic bone marrow transplantation. Blood 2002;100(10):3479-82.
385
Search WWH ::
Custom Search